Lunit

Lunit FCF Growth

The Year-over-Year Free Cash Flow Growth of Lunit (328130.KQ) as of Nov 15, 2026 is 35.30 %. In the previous year, Year-over-Year Free Cash Flow Growth was -399.96 % — a change of -108.83% (higher).

FCF Growth

35.30 %

YoY

-108.83%

Last updated:

Year-over-Year Free Cash Flow Growth of Lunit is 2024 35.30 % . Year-over-Year Free Cash Flow Growth of Lunit was 2023 -399.96 % . It decreases by -108.83% higher compared to the previous year.

The Lunit FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
-68.98 KRW
Jan 1, 2021
-90.22 KRW
Jan 1, 2022
98.03 KRW
Jan 1, 2023
-399.96 KRW
Jan 1, 2024
35.30 KRW
The Lunit FCF Growth history
YEARFCF GrowthYoY
35.30 %-108.83%
-399.96 %-508.00%
98.03 %-208.66%
-90.22 %+30.79%
-68.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Year-over-Year Free Cash Flow Growth of Lunit is 35.30 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Lunit since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Lunit historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Lunit

All Key Metrics — Lunit